The GH-2000 score has been developed as a powerful and unique technique for the detection of growth hormone misuse by sportsmen and women. The score depends upon the measurement of two growth hormone sensitive markers, insulin-like growth factor-I and the amino-terminal pro-peptide of type III collagen. It also includes a term to adjust for the age of the athlete. Decision limits for the GH-2000 score have been developed and are incorporated into the guidelines of the World Anti-Doping Agency. These decision limits are derived by setting a 1 in 10,000 false-positive rate rule. As these decision limits are estimated from samples of GH-2000 scores, they carry uncertainty. In previous work, this uncertainty has been addressed by establishing an upper 95% confidence interval for the true decision limits based on a normal approximation which has been shown to be appropriate if sample sizes are large (such as 1000 and above). Here, we show that these approximations, whether reasonable or not, can be entirely avoided by developing an upper 95% confidence interval for the true decision limits using an approach based upon the t-distribution. While there are considerable differences for smaller sample sizes, these become negligible when the sample size is large such as 1000 and above.
Introduction
Growth hormone (GH) is a powerful anabolic agent of considerable therapeutic value but also misused in sport for its anabolic and lipolytic properties. 1 In order to preserve the fairness of competition, its use is prohibited by the World Anti-Doping Agency 2 and there is a need for methods to detect its misuse. Two methods are presently available and approved by the World Anti-Doping Agency (WADA); the isoform test developed by Bidlingmaier et al. 3 (see also WADA 2, 4 ) and the GH-2000 biomarker test developed by the GH-2000 and GH-2004 projects. 5 The latter method depends upon the measurement of two GH sensitive markers, insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP), both of which rise in response to exogenous GH administration. 6, 7 The measured concentrations of the biomarkers are combined in sex-specific and age-adjusted discriminant functions, which allow for the calculation of a score (the GH-2000 score) on which basis the compliance of the samples' analytical result is determined. The paper is organized as follows. In section 2, further details on the GH-2000 score construction are given and the background of decision limit construction to detect GH misuse is reviewed. A crucial element in the decision limit construction is how uncertainty is incorporated. In section 3, we present a new and alternative way of incorporating uncertainty in an exact statistical way, given a desired false-positive rate (FPR) of 1 in 10,000. The paper closes with a discussion putting these findings in perspective.
2 Background and state-of-the-art approach for constructing the decision limits for GH misuse
The GH-2000 score has been developed in Powrie et al., 8 Erotokritou-Mulligan et al. 9 and Holt et al. 5 It has the theoretical or model form
where the known coefficients i 's have different values for male and female athletes. IGF-I and P-III-NP are generic terms for the two serum proteins to be measured. This measurement process is done by choosing a specific assay so that assay-specific forms of the GH-2000 score are available and the basis of the data generating process. Currently, there are three IGF-I assays and two P-III-NP assays approved by WADA. The IGF-I assays are:
.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
. Immunotech A15729 IGF-I IRMA (Immunotech SAS, Marseille, France) . Immunodiagnostic Systems iSYS IGF-I (Immunodiagnostics Systems Limited, Boldon, UK)
The P-III-NP assays are:
. UniQ IM P-III-NP RIA (Orion Diagnostica, Espoo, Finland) . Siemens ADVIA Centaur P-III-NP (Siemens Healthcare Laboratory Diagnostics, Camberley, UK)
For more details and background on these assays, see Holt et al. 5 As any GH-2000 score requires a pair of IGF-I assay and P-III-NP assay, there are six possible GH-2000 scores. Depending on the available technology, laboratories choose the appropriate GH-2000 score for evaluating their samples and decision limits have been developed for all six GH-2000 scores in Holt et al. 5 Intra-subject and inter-subject variability are important issues for the performance of the forensic test and have been considered carefully during its development. The intra-subject variability can be divided into biological and analytical variability, both of which have been studied. We have previously investigated the intra-subject biological variability of the GH-2000 scores and its components. The intra-individual variability for IGF-I ranged between 14 and 16% while the variability for P-III-NP was 7-18%. 10 The overall mean intra-individual variability of the GH-2000 score was less than 0.6 units. Furthermore, within-assay and between-assay variability has been determined by the WADA-accredited Drug Control Centre at Kings College London. In order to minimise assay variability between laboratories, WADA also assesses laboratory performance by the use of quality control samples before approving them to undertake this test.
Currently, the test is designed to be used on a one-off basis and for this, within-subject variability is less relevant. However, the anti-doping authorities are developing a biological passport whereby each individual acts as his or her own control. The biological passport currently has haematological and steroidal modules but this could be expanded to include an endocrine module. 11 The premise of the test is based on the variability between athletes. We have studied the mean and standard deviation (SD) of a large population of elite athletes in order to determine when the GH-2000 score is not biologically plausible without doping.
Note that the GH-2000 score consists of a linear discriminant function containing one of the approved assays for each of IGF-I and P-III-NP and an age correction term. The age correction is required because GH secretion and markers of its action rise during childhood and reach a peak in early adulthood before declining again. 12 Without an adjustment for age, younger athletes are placed at a disadvantage. The inverse term for age is designed to adjust for age so that the score becomes independent of age. This is important in order to make the test applicable to athletes of all ages. Again, details are available including an improved age-adjustment in Bo¨hning et al. 13 In the following, we assume that a GH-2000 score from an elite athlete without GH misuse is available and denote it by X. We assume further, and this is supported by substantial empirical evidence, that X of an athlete without GH misuse is normally distributed. Let the mean of X be denoted by and the variance of X by 2 . Due to a requirement of WADA, 2 it is desired to have a FPR of 1 in 10,000 which leads to a critical value c with the property that the probability for X exceeding c is 1 in 10,000, that is,
See also Figure 1 for an illustration. We can write equation (2) as
which can further be written as
where ÈðzÞ is cumulative distribution function of a standard normal distribution. As ÈðzÞ ¼ 0:9999 is solved by z ¼ 3.72, we find
or equivalently c ¼ þ 3:72 ð6Þ
Clearly, had and been known, c ¼ þ 3:72 would be the decision limit for us as it has a 1 in 10,000 FPR1. However, and are unknown and need to be estimated by their sample estimates "
x and s, the sample mean and sample SD, respectively. For that purpose, it is assumed that a sample of GH-2000 scores from elite athletes without GH misuse of size n is available. Furthermore, each elite athletes sample was only analysed once so that n refers to number of athletes. As we need to replace and 2 by their respective sample estimates, we only achieve an estimated critical valuê c, namelyĉ
Asĉ is a random quantity, there is no guarantee that " x þ 3:72s ! þ 3:72 (in order to ensure at most 1 in 10, 000 FPR). Hence, it is required to incorporate this uncertainty into the construction of the decision limit. This can be accomplished by using an additional uncertainty term u such that
that is, we aim to construct an upper 95% confidence interval for the critical value c associated with the exact 1 in 10,000 FPR. In other words, we would like to construct an upper value, so that the true critical value associate with a FPR of 1 in 10,000 is equal or below this upper value with a pre-specified confidence level 0.95. Now, equation (8) is equivalent with
where we set k ¼ 3.72. Assuming that " X þ kS is (approximately) normal we can consider equation (9) and solve it for u, namely Àu= ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
What remains is to find the variance of " X þ kS. In Appendix 1, we recall the arguments leading to the following approximation of Varð " X þ kSÞ, which can be found under normality to be
and 2 n ð1 þ k 2 =2Þ, the right-hand side of equation (11), can be readily estimated by s 2 n ð1 þ k 2 =2Þ. Hence, we are able to provide a more concrete form of equation (10), namely
leading to the final decision limit
Clearly, with increasing sample size n, the uncertainty adjustment will lose its importance as it is inversely related to ffiffi ffi n p , and the decision limit simply becomes " x þ ks as n approaches infinity.
An alternative and exact approach
To rephrase the problem, we need h such that
where X 1 , Á Á Á, X n are independent and identically distributed, each having a normal distribution X i $ Nð, 2 Þ for i ¼ 1, Á Á Á, n. It follows that " X $ Nð, 2 =nÞ and ðn À 1ÞS 2 = 2 $ 2 nÀ1 , the latter denoting a chi-square distribution with n -1 degrees of freedom. From the expression in equation (14), a reader who is familiar with the statistical methodology of tolerance sets (see for example, Hahn and Meeker 14 or Krishnamoorthy and Mathew 15 ) will easily realize that what we want is the 0.9999-content 95% confidence upper tolerance limit for a normal distribution, which is also a special case of inference about quantiles of a normal distribution.
Next, for the convenience of the reader, we give a simple derivation of this upper tolerance limit. Logically equivalent transformations of the statement " X þ hS ! þ k in equation (14) lead to
and
and finally
Note that Z is a standard normal random variable: Z $ Nð0, 1Þ. Hence equation (17) becomes equivalent to
From the definition of the non-central t-distribution given in the Appendix 2, it is clear that T ¼ ZÀ ffiffi n p k S= has a non-central t-distribution with ðn À 1Þ df and parameter of non-centrality À ffiffi ffi n p k. Now, it is easy to determine h to yield that PðT ! Àh ffiffi ffi n p Þ ¼ 0:95 which is equivalent to PðT 5 À h ffiffi ffi n p Þ ¼ 0:05. Hence, we can find h as h ¼ ÀÉ
, namely the fifth percentile of the non-central t-distribution with ðn À 1Þ degrees of freedom and parameter of non-centrality À ffiffi ffi n p k. Here, É df; ðtÞ denotes the cumulative distribution function of the t-distribution with df degrees of freedom and parameter of non-centrality . This leads to the new form of decision limit as
It is interesting to compare the decision limit in equation (20) and the decision limit used currently Table 1 presents some comparative results. It can be seen that there are considerable differences between the two for small sample sizes but these become small for n ¼ 100 and above. The differences become negligible for n ¼ 1000 and above.
True-false-positive rate
If the true population values and 2 would be known, a decision limit of the form þ 3:72 would provide an exact FPR of 1 in 10,000. However, and 2 have to be estimated from a sample leading to statistical error. To adjust for this error, an upper 95% confidence limit is chosen as the decision limit. In fact, the decision limit has been developed as " X þ hS where h is either given in equation (20) where " X and S are sample mean and sample SD of a sample of GH-2000 score measurements X 1 , . . ., X n for n athletes. Note that X is not part of the sample but assumed to arise from the same population the sample has come from. Note that we have the equivalence
is distributed as 2 with n -1 degrees of freedom. This leads to the fact that
has a t-distribution with ðn À 1Þ degrees of freedom. It follows that
where É ð:Þ is the cumulative distribution function of a t-distribution with degrees of freedom. Hence, we have an easy formula for calculating the TFPR.
In Table 2 , we have calculated the TFPR for selected values of n. We see that the exact method equation (20) meets the 1 in 10,000 target even for small sample sizes, whereas the conventional method equation (13) needs slightly larger sample sizes. It is pointed out here that, for both methods, convergence to the target value of 1 in 10,000 is from below which emphasizes that the uncertainty term is chosen appropriately.
Discussion
We have developed a new and exact form of decision limits to cope with uncertainty in the decision limit estimate based on the GH-2000 score for GH misuse. The decision limits currently in use, which were developed using the large sample method, are based on sample sizes of at least 1000. Hence, the new multiplier, developed on the basis of the non-central t-distribution, is not substantially different for large sample sizes and there is no need to modify the current decision limits as implemented in the WADA guidelines as these are based on large sample sizes. However, the new approach is still valuable. The conventional approach uses approximations at two places:
. It is assumed that " X þ kS is normally distributed. This will only hold approximately and the approximation will be not good for small sample size. Of course, using the central limit theorem here, the approximation is well defendable for larger sample sizes. However, there is always debate on what establishes a large sample size. . In computing the variance of S, we are using a further approximation by means of applying the -method. This might be reasonable or not. Recent simulation work shows that for sample sizes of 1000 and above, themethod based approximation discussed in the Appendix 1 is quite reasonable.
17
The major benefit of the new approach is making these two approximations unnecessary. It is clear that these decision limits more defendable, for example in court cases, as they are exact for any sample size n, large or small. Clearly, a large sample size (such as 1000 or more) is preferable to a small sample size. However, it needs to be seen that the conventional method equation (13) still uses a normality assumption for its development (as does the new method equation (20)), but the new method avoids the approximations mentioned above.
It is interesting to note, though, that for small sample sizes, the new approach is more suitable. Hence, this might be the way to proceed when new assays come into use replacing older ones and new decision limits have to be calculated.
Another issue is the choice of the upper 95% confidence limit as coping with the statistical uncertainty. This was suggested in Erotokritou-Mulligan et al. 9 presumingly for no other reason than that this is the standard statistical significance level. In addition, this proposal was accepted by WADA and has become part of their guidelines. 2 Clearly, increasing the confidence level would further enlarge the decision limit, but this would also lead to an increase in the false-negative rate (FNR) and in the investigation of the TFPR in section 4 clearly shows that this is not necessary as the current confidence level ensures convergence to the TFPR from below.
It is clear that a larger decision limit will increase the FNR. Hence, the conventional method equation (13) might have a smaller FNR as the associated decision limit is smaller than the exact method equation (20), but this is purely because the conventional method is approximate and has a larger FPR than the exact method which guarantees the 1/10,000 FPR for any reasonable sample size. The FNR has been investigated previously; 8, 18 here, we are not able to make any statements on the FNR as this would require GH-2000 scores from confirmed positive athletes.
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